

100-0246 - Dorsomorphin

Revision Date 18-Jan-2023 Revision Number 1.1

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING

Product identifier

Product Name Dorsomorphin

Other means of identification

Catalog Number 100-0246

Document Number 10000007641

Synonyms Compound C; 6-[4-[2-(1-piperidinyl)ethoxy]phenyl]-3-(4-pyridinyl)-pyrazolo[1,5-a]pyrimidine;

Recommended use of the chemical and restrictions on use

Recommended Use Laboratory chemicals

Details of the supplier of the safety data sheet

Manufacturer/Supplier

STEMCELL Technologies Canada Inc. Suite 500 - 1618 Station Street Vancouver, British Columbia V6A 1B6 Canada

Emergency telephone number

Emergency Telephone 1-800-667-0322

2. HAZARDS IDENTIFICATION

Classification

This chemical is considered hazardous by the 2012 OSHA Hazard Communication Standard (29 CFR 1910.1200)

Acute toxicity - Oral	Category 4
Acute toxicity - Dermal	Category 4
Acute toxicity - Inhalation (Dusts/Mists)	Category 4

Hazards not otherwise classified (HNOC)

Not applicable

Label elements



100-0246 - Dorsomorphin

Revision Date 18-Jan-2023 Revision Number 1.1

Warning

Hazard statements

Harmful if swallowed
Harmful in contact with skin
Harmful if inhaled



Appearance Crystalline

Physical state Solid

Odor No data available

Precautionary Statements - Prevention

Wash face, hands and any exposed skin thoroughly after handling Do not eat, drink or smoke when using this product Wear protective gloves/protective clothing Avoid breathing dust/fume/gas/mist/vapors/spray Use only outdoors or in a well-ventilated area

IF ON SKIN: Wash with plenty of water and soap
Call a POISON CENTER or doctor if you feel unwell
Take off contaminated clothing and wash it before reuse
IF INHALED: Remove person to fresh air and keep comfortable for breathing
Call a POISON CENTER or doctor if you feel unwell
IF SWALLOWED: Call a POISON CENTER or doctor if you feel unwell
Rinse mouth

Precautionary Statements - Disposal

Dispose of contents/container to an approved waste disposal plant

Other Information

Not applicable

Unknown acute toxicity

0 % of the mixture consists of ingredient(s) of unknown toxicity

- 0 % of the mixture consists of ingredient(s) of unknown acute oral toxicity
- 0 % of the mixture consists of ingredient(s) of unknown acute dermal toxicity
- 0 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (gas)
- 0 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (vapor)
- 0 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (dust/mist)

3. COMPOSITION/INFORMATION ON INGREDIENTS



100-0246 - Dorsomorphin

Revision Date 18-Jan-2023 Revision Number 1.1

-

Substance

Synonyms Compound C;.

6-[4-[2-(1-piperidinyl)ethoxy]phenyl]-3-(4-pyridinyl)-pyrazolo[1,5-a]pyrimidine;.

Chemical name	CAS No.	Weight-%
6-[4-(2-Piperidin-1-ylethoxy)phenyl]-3-pyridin-4-ylpy	866405-64-3	100
razolo[1,5-a]pyrimidine		

^{*}The exact percentage (concentration) of composition has been withheld as a trade secret.

4. FIRST AID MEASURES

Description of first aid measures

General advice Show this safety data sheet to the doctor in attendance.

Inhalation If breathing has stopped, give artificial respiration. Get medical attention immediately.

Remove to fresh air. If symptoms persist, call a physician.

Eye contactRinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids.

Consult a physician.

Skin contact Wash off immediately with plenty of water for at least 15 minutes. If symptoms persist, call a

physician.

Ingestion Do NOT induce vomiting. Clean mouth with water and drink afterwards plenty of water.

Never give anything by mouth to an unconscious person. Get medical attention.

Self-protection of the first aider Ensure that medical personnel are aware of the material(s) involved, take precautions to

protect themselves and prevent spread of contamination. Avoid breathing

dust/fume/gas/mist/vapors/spray. Use personal protective equipment as required. See

section 8 for more information.

Most important symptoms and effects, both acute and delayed

Symptoms Coughing and/ or wheezing. Difficulty in breathing.

Indication of any immediate medical attention and special treatment needed

Note to physicians Treat symptomatically.

5. FIRE-FIGHTING MEASURES



100-0246 - Dorsomorphin

Revision Date 18-Jan-2023 Revision Number 1.1

Suitable Extinguishing Media Use extinguishing measures that are appropriate to local circumstances and the

surrounding environment.

Unsuitable extinguishing media CAUTION: Use of water spray when fighting fire may be inefficient.

Specific hazards arising from the

chemical

No information available.

Explosion data

Sensitivity to Mechanical Impact None. Sensitivity to Static Discharge None.

Special protective equipment for

fire-fighters

Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures

Personal precautions Avoid contact with skin, eyes or clothing. Ensure adequate ventilation. Avoid generation of

dust. Do not breathe dust. Use personal protective equipment as required.

Other Information Refer to protective measures listed in Sections 7 and 8.

Environmental precautions

Environmental precautions Prevent further leakage or spillage if safe to do so.

Methods and material for containment and cleaning up

Methods for containment Prevent further leakage or spillage if safe to do so.

Methods for cleaning up Pick up and transfer to properly labeled containers.

Prevention of secondary hazards Clean contaminated objects and areas thoroughly observing environmental regulations.

7. HANDLING AND STORAGE

Precautions for safe handling

Advice on safe handling Avoid contact with skin, eyes or clothing. Handle in accordance with good industrial hygiene

and safety practice. Avoid breathing dust/fume/gas/mist/vapors/spray. Avoid generation of dust. Ensure adequate ventilation. Do not eat, drink or smoke when using this product.



100-0246 - Dorsomorphin

Revision Date 18-Jan-2023 Revision Number 1.1

Conditions for safe storage, including any incompatibilities

Storage Conditions Store locked up. Store in accordance with information listed on the Product Information

Sheet (PIS). Keep out of the reach of children.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Control parameters

Exposure Limits The following ingredients are the only ingredients of the product above the cut-off level (or

level that contributes to the hazard classification of the mixture) which have an exposure

limit applicable in the region for which this safety data sheet is intended or other recommended limit. At this time, the other relevant constituents have no known exposure

limits from the sources listed here.

Appropriate engineering controls

Engineering controls Showers

Eyewash stations Ventilation systems.

Individual protection measures, such as personal protective equipment

Eye/face protection Wear safety glasses with side shields (or goggles).

Hand protection Wear suitable gloves.

Skin and body protection Wear suitable protective clothing. Long sleeved clothing.

Respiratory protection No protective equipment is needed under normal use conditions. If exposure limits are

exceeded or irritation is experienced, ventilation and evacuation may be required.

General hygiene considerations Avoid contact with skin, eyes or clothing. Wear suitable gloves and eye/face protection.

Avoid breathing dust/fume/gas/mist/vapors/spray. Do not eat, drink or smoke when using

this product.

9. PHYSICAL AND CHEMICAL PROPERTIES

Information on basic physical and chemical properties

Physical state Solid Appearance Crystalline



100-0246 - Dorsomorphin

Revision Date 18-Jan-2023 Revision Number 1.1

Color
No information available
No data available

Odor threshold No data available

<u>Property</u> <u>Values</u> <u>Remarks • Method</u>

No data available рΗ None known Melting point / freezing point No data available None known None known No data available Boiling point / boiling range No data available Flash point None known **Evaporation rate** No data available None known Flammability (solid, gas) Product is not flammable. None known

Flammability Limit in Air None known

Upper flammability limit: No data available
Lower flammability limit: No data available

Lower flammability limit:No data availableVapor pressureNo data availableNone knownVapor densityNo data availableNone knownRelative densityNo data availableNone knownWater solubilityNo data availableNone known

Water solubility
No data available
None known
Solubility in other solvents
No data available

~2.5 mg/mL in DMF; ~1 mg/mL in
None known

DMSO (sonicated)

Partition coefficientNo data availableNone knownAutoignition temperatureNo data availableNone knownDecomposition temperatureNo data availableNone knownKinematic viscosityNo data availableNone knownDynamic viscosityNo data availableNone known

Explosive properties No data available

Oxidizing properties No information available

Other Information

Softening point No information available

Molecular weight 399.5 Molecular formula C24H25N5O

VOC Content (%)
Liquid Density
No information available
No information available
No information available

10. STABILITY AND REACTIVITY

Reactivity No information available.

Chemical stability Stable under recommended transport or storage conditions.

Possibility of hazardous reactions None under normal processing.

Hazardous polymerization Hazardous polymerization does not occur.

Conditions to avoid Excessive heat.



100-0246 - Dorsomorphin

Revision Date 18-Jan-2023 Revision Number 1.1

Incompatible materials Strong oxidizing agents.

Hazardous decomposition products Carbon oxides. Nitrogen oxides (NOx).

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Product Information

Inhalation Specific test data for the substance or mixture is not available. Harmful by inhalation.

(based on components).

Eye contact Specific test data for the substance or mixture is not available.

Skin contact May be harmful if absorbed through the skin. Harmful in contact with skin. (based on

components).

Ingestion Specific test data for the substance or mixture is not available. Harmful if swallowed. (based

on components).

Symptoms related to the physical, chemical and toxicological characteristics

Symptoms Coughing and/ or wheezing.

Numerical measures of toxicity

Acute toxicity

The following values are calculated based on chapter 3.1 of the GHS document

 ATEmix (oral)
 500.00 mg/kg

 ATEmix (dermal)
 1,100.00 mg/kg

 ATEmix (inhalation-dust/mist)
 1.50 mg/l

Unknown acute toxicity 0 % of the mixture consists of ingredient(s) of unknown toxicity

0 % of the mixture consists of ingredient(s) of unknown acute oral toxicity

- 0 % of the mixture consists of ingredient(s) of unknown acute dermal toxicity
- 0 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (gas)
- 0 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (vapor)
- 0 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (dust/mist)

Product Information

Delayed and immediate effects as well as chronic effects from short and long-term exposure

Skin corrosion/irritationNo information available.

Product Information



100-0246 - Dorsomorphin

Revision Date 18-Jan-2023 Revision Number 1.1

Serious eye damage/eye irritation No information available.

Product Information

Respiratory or skin sensitization No information available.

Product Information

Germ cell mutagenicity No information available.

Product Information

Carcinogenicity No information available.

Reproductive toxicity No information available.

Product Information

STOT - single exposure No information available.

Product Information

STOT - repeated exposureNo information available.

Product Information

Aspiration hazard No information available.

RTECS #

12. ECOLOGICAL INFORMATION

Ecotoxicity The environmental impact of this product has not been fully investigated.

UR0772270

Product Information

Persistence and degradability No information available.

Bioaccumulation There is no data for this product.

Other adverse effects No information available.

13. DISPOSAL CONSIDERATIONS

Waste treatment methods

Waste from residues/unused

products

Dispose of in accordance with local regulations. Dispose of waste in accordance with

environmental legislation.

Contaminated packagingDo not reuse empty containers.



100-0246 - Dorsomorphin

Revision Date 18-Jan-2023 Revision Number 1.1

14. TRANSPORT INFORMATION

Note: Transport in accordance with local, state, and federal regulations.

DOTNot regulatedTDGNot regulated

MEX Not regulated

ICAO (air) Not regulated

<u>IATA</u> Not regulated

<u>IMDG</u> Not regulated

RID Not regulated

ADR Not regulated

ADN Not regulated

15. REGULATORY INFORMATION

International Inventories

TSCA Does not comply Does not comply **DSL/NDSL** Does not comply **EINECS/ELINCS ENCS** Does not comply **IECSC** Does not comply Does not comply **KECL PICCS** Does not comply **AICS** Does not comply

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

DSL/NDSL - Canadian Domestic Substances List/Non-Domestic Substances List

EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

ENCS - Japan Existing and New Chemical Substances

IECSC - China Inventory of Existing Chemical Substances

KECL - Korean Existing and Evaluated Chemical Substances

PICCS - Philippines Inventory of Chemicals and Chemical Substances

AICS - Australian Inventory of Chemical Substances



100-0246 - Dorsomorphin

Revision Date 18-Jan-2023 Revision Number 1.1

US Federal Regulations

SARA 313

Section 313 of Title III of the Superfund Amendments and Reauthorization Act of 1986 (SARA). This product does not contain any chemicals which are subject to the reporting requirements of the Act and Title 40 of the Code of Federal Regulations, Part 372.

SARA 311/312 Hazard Categories

Acute health hazard	Yes
Chronic Health Hazard	No
Fire hazard	No
Sudden release of pressure hazard	No
Reactive Hazard	No

CWA (Clean Water Act)

This product does not contain any substances regulated as pollutants pursuant to the Clean Water Act (40 CFR 122.21 and 40 CFR 122.42).

CERCLA

This material, as supplied, does not contain any substances regulated as hazardous substances under the Comprehensive Environmental Response Compensation and Liability Act (CERCLA) (40 CFR 302) or the Superfund Amendments and Reauthorization Act (SARA) (40 CFR 355). There may be specific reporting requirements at the local, regional, or state level pertaining to releases of this material.

US State Regulations

California Proposition 65

This product does not contain any Proposition 65 chemicals.

U.S. State Right-to-Know Regulations

US State RegulationsThis product does not contain any substances regulated by state right-to-know regulations

U.S. EPA Label Information

EPA Pesticide Registration Number Not applicable

16. OTHER INFORMATION, INCLUDING DATE OF PREPARATION OF THE LAST REVISION

Prepared By, Quality Control. STEMCELL Technologies Canada Inc.

Revision Date 18-Jan-2023



100-0246 - Dorsomorphin

Revision Date 18-Jan-2023 Revision Number 1.1

Revision Note No information available. Disclaimer

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text. STEMCELL Technologies Inc. shall not be held liable for any damage resulting from handling or from contact with the product.

End of Safety Data Sheet